Policy & Regulation
Delonix Bioworks launches Phase 1 trial of next-generation MenB OMV vaccine DX-104
31 March 2026 - Delonix Bioworks, a clinical-stage biotechnology company developing genetically engineered bacterial vaccines, announced on Monday the initiation of first-in-human (FIH) dosing in a Ph...
Hengrui Pharma and Braveheart Bio report positive Phase 2 results for HRS/BHB-1893 in oHCM
31 March 2026 - Pharmaceutical company Hengrui Pharma and Braveheart Bio, a late clinical-stage biotechnology company developing novel therapeutics for hypertrophic cardiomyopathy and related conditio...
Innovent and Ollin Biosciences report IBI324 study data in wAMD and DME
31 March 2026 - Chinese biopharmaceutical company Innovent Biologics Inc (HKEX:01801) announced on Monday that its US partner Ollin Biosciences has reported final, 20-week study completion data from i...
Fusion Antibodies signs GBP250,000 IP transfer deal with Finn Therapeutics
30 March 2026 - Belfast-based contract research organisation Fusion Antibodies plc (AIM: FAB) reported on Monday that it has entered into an intellectual property transfer agreement with Finn Therapeu...
GSK's bepirovirsen accepted for review in China as potential Hepatitis B functional cure
30 March 2026 - Biopharmaceutical company GSK plc (LSE: GSK) (NYSE: GSK) announced on Monday that China's National Medical Products Administration has accepted for review a new drug application f...
4DMedical secures EU approval for CT:VQ as EUR83m funding fuels European expansion
30 March 2026 - Cardiothoracic imaging software provider 4DMedical Limited (ASX: 4DX) declared on Monday that it has received CE Mark certification for its CT:VQ imaging technology, enabling commercia...